

AMENDMENTS TO THE CLAIMS:

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of eliciting an immune response against an EphA2-expressing cell, said method comprising administering to an individual a composition comprising:

- (a) an EphA2 antigenic peptide in an amount effective to elicit an immune response against an EphA2-expressing cell;
- (b) an EphA2 antigenic peptide expression vehicle in an amount effective to elicit an immune response against an EphA2-expressing cell;
- (c) antigen presenting cells sensitized with an EphA2 antigenic peptide; or
- (d) an anti-idiotypic antibody or antigen-binding fragment thereof which immunospecifically binds to an idiotype of an anti-EphA2 antibody in an amount effective to elicit an immune response against an EphA2-expressing cell.

2. (Original) The method of claim 1, wherein the EphA2 antigenic peptide is not TLADFDPRV (SEQ ID NO:3); VLLLVLGV (SEQ ID NO:4); VLAGVGFFI (SEQ ID NO:5); IMNDMPIYM (SEQ ID NO:6); SLLGLKDQV (SEQ ID NO:7); WLVPICQL (SEQ ID NO:8); LLWGCALAA (SEQ ID NO:9); GLTRTSVTV (SEQ ID NO:10); NLYYAESDL (SEQ ID NO:11); KLNVEERSV (SEQ ID NO:12); IMGQFSHN (SEQ ID NO:13); YSVCNVMSG (SEQ ID NO:14); MQNIMNDMP (SEQ ID NO:15); EAGIMGQFSHNIIR (SEQ ID NO:16); PIYMYSVCNVMSG (SEQ ID NO:17); or DLMQNIMNDMPIYMYS (SEQ ID NO:18).

3. - 7. (Cancelled)

8. (Currently Amended) The method of claim 7, wherein the expression vehicle is a nucleic acid encoding said EphA2 antigenic peptide operably linked to a promoter.

9.- 13. (Cancelled)

14. (Currently Amended) The method of claim 71, wherein the expression vehicle is an infectious agent comprising a nucleic acid, said nucleic acid comprising a nucleotide sequence encoding said EphA2 antigenic peptide operably linked to a promoter.
15. (Original) The method of claim 14, wherein the sequence encoding said EphA2 antigenic peptide is codon-optimized for expression in said infectious agent.
16. (Currently Amended) The method of claim 14, wherein the infectious agent is coated with a reagent that targets the infectious agent to EphA2-expressing cells or to antigen presenting cells.
17. – 18. (Cancelled)
19. (Currently Amended) The method of claim 14, wherein the infectious agent is a bacterium or a virus.
20. (Currently Amended) The method of claim 19, wherein the bacterium or virus is attenuated.
21. (Original) The method of claim 19, wherein the nucleic acid comprises a nucleotide sequence encoding a secretory signal operatively linked to the sequence encoding the EphA2 antigenic peptide.
22. – 23. (Cancelled)
24. (Original) The method of claim 19, wherein the bacterium is not *Listeria*.
25. – 31. (Cancelled)
32. (Original) The method of claim 71, wherein the expression vehicle is a mammalian cell comprising a recombinant nucleic acid, said nucleic acid comprising a nucleotide sequence encoding said EphA2 antigenic peptide.
33. - 42 (Cancelled)

43. (Currently Amended) The method of claim ~~36~~1, wherein the antigen presenting cells are macrophages or dendritic cells.

44. (Cancelled)

45. (Currently Amended) The method of claim 1, ~~7, or 36~~, wherein the individual has cancer or a non-neoplastic hyperproliferative disorder.

46. – 52. (Cancelled)

53. (Currently Amended) A method of treating a human individual having a hyperproliferative disorder of EphA2-expressing cells or a disease involving aberrant angiogenesis, said method comprising administering to an individual a composition comprising:

- (a) an EphA2 expression vehicle in an amount effective to treat a hyperproliferative disorder of EphA2-expressing cells or a disease involving aberrant angiogenesis;
- (b) an EphA2 antigenic peptide in an amount effective to treat a hyperproliferative disorder of EphA2-expressing cells or a disease involving aberrant angiogenesis;
- (c) antigen presenting cells sensitized with an EphA2 antigenic peptide in an amount effective to treat a hyperproliferative disorder of EphA2-expressing cells or a disease involving aberrant angiogenesis;
- (d) an anti-idiotypic antibody or antigen-binding fragment thereof which immunospecifically binds to an idiotype of an anti-EphA2 antibody in an amount effective to elicit treat a hyperproliferative disorder of EphA2-expressing cells or a disease involving aberrant angiogenesis; or
- (e) antibodies produced by administering an EphA2 vaccine to a host in an amount effective to treat a hyperproliferative disorder of EphA2-expressing cells or a disease involving aberrant angiogenesis.

54. – 56 (Cancelled)

57. (Currently Amended) The method of claim ~~53, 54, 55, or 56~~, wherein the individual ~~has~~ hyperproliferative disorder is cancer.

58. – 63. (Cancelled)

64. (Currently Amended) The method of ~~any one of claim 1, 7, 36, or 53, 54, and 55,~~ wherein the EphA2 ~~polypeptide~~ antigenic peptide comprises full length EphA2.

65. (Currently Amended) The method of any ~~any one of claims claim~~ claim 1, 7, 36, or 53, 54, and 55, wherein the EphA2 ~~polypeptide~~ antigenic peptide comprises: (a) the extracellular domain or intracellular domain of EphA2, or (b) the intracellular domain and extracellular domain of EphA2 and lacks the transmembrane domain.

66. (Cancelled)

67. (Currently Amended) The method of claim ~~66-65,~~ wherein the ~~polypeptide~~ antigenic peptide lacks tyrosine kinase activity.

68. (Currently Amended) The method of claim 67, wherein the EphA2 ~~polypeptide~~ antigenic peptide lacks tyrosine kinase activity due to a lysine to methionine substitution at position 646 of EphA2.

69. (Currently Amended) The method of ~~any one of claims claim~~ claim 1, 7, 36, or 53, 54, and 55, wherein the EphA2 ~~polypeptide~~ antigenic peptide is a chimeric polypeptide comprising at least an antigenic portion of EphA2 and a second polypeptide.

70. (Currently Amended) The method of claim ~~52 or 56~~ 53, wherein the EphA2 antibody immunospecifically binds to an epitope in the extracellular domain or the intracellular domain of EphA2.

71. – 89. (Cancelled)

90. A method of producing antibodies that immunospecifically bind to EphA2 comprising administering an EphA2 vaccine to a host.

91. – 92. (Cancelled)